Table 3.
Cox Models for Months to Death
Model 0 | Model 1 | Model 2 | Model 3* | |
---|---|---|---|---|
N | 6523 | 6791 | 6523 | 2758 |
n (%) Censored | 1447 (22.2%) | 1496 (22.0%) | 1447 (22.2%) | 705 (25.6%) |
Variable | HR (95% CI)** | HR (95% CI) | HR (95% CI) | HR (95% CI) |
Treatment Decision (vs. Treatment/No Hospice [Group 3]): | ||||
No Treatment/No Hospice [Group 1] | 1.08 (1.002–1.17) | 1.61 (1.48–1.75) | 1.40 (1.23–1.58) | |
Treatment/Hospice [Group 4] | 2.98 (2.68–3.31) | 2.09 (1.88–2.33) | 1.99 (1.69–2.35) | |
No Treatment/Hospice [Group 2] | 3.40 (3.13–3.69) | 2.90 (2.66–3.18) | 2.84 (2.48–3.25) | |
Total ADL score: | ||||
First Assessment | 1.04 (1.03–1.05) | |||
Improvement | 0.93 (0.92–0.95) | |||
Male (vs. Female) | 1.16 (1.10–1.23) | 1.17 (1.11–1.24) | 1.20 (1.10–1.32) | |
Age at Index Admission (10 years) | 1.19 (1.14–1.23) | 1.06 (1.02–1.11) | ||
Months between Diagnosis and Index Admission | 0.93 (0.90–0.96) | 0.93 (0.91–0.96) | 0.94 (0.90–0.98) | |
SES | ||||
Median Income ($10,000) | 0.98 (0.97–0.99) | 0.98 (0.97–0.99) | ||
Charlson Comorbidity Index Categories | 1.07 (1.05–1.10) | 1.05 (1.03–1.08) | ||
Cancer Type (vs. Colorectal) | ||||
Lung | 1.87 (1.72–2.03) | 1.88 (1.73–2.04) | 2.06 (1.81–2.35) | |
Pancreas | 2.29 (2.05–2.57) | 2.20 (1.96–2.46) | 2.36 (1.97–2.84) | |
Bladder | 1.89 (1.64–2.18) | 1.80 (1.56–2.07) | 1.86 (1.51–2.30) | |
Cancer Stage (vs. Stage IV) | ||||
Stage II | 0.34 (0.31–0.37) | 0.35 (0.32–0.38) | 0.38 (0.33–0.43) | |
Stage III | 0.52 (0.48–0.56) | 0.56 (0.52–0.60) | 0.58 (0.52–0.66) | |
Grade (vs. 9) | ||||
1 | 0.43 (0.36–0.52) | 0.48 (0.40–0.58) | 0.48 (0.36–0.64) | |
2 | 0.61 (0.56–0.67) | 0.66 (0.60–0.73) | 0.70 (0.61–0.82) | |
3 | 0.87 (0.80–0.94) | 0.93 (0.86–1.005) | 0.97 (0.86–1.10) | |
4 | 0.90 (0.78–1.03) | 0.98 (0.85–1.12) | 1.16 (0.94–1.43) | |
Index LOS (10 days) | 1.07 (1.03–1.10) | 1.09 (1.05–1.13) |
Many cases were not used in the model since improvement in total ADL score was available for only 2758 patients.
Hazard Ratio (95% Confidence Interval)